- Home
- VRNT vs GPCR Comparison
VRNT vs GPCR Comparison
Compare VRNT & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNT
- GPCR
- Stock Information
- Founded
- VRNT 1994
- GPCR 2016
- Country
- VRNT United States
- GPCR United States
- Employees
- VRNT N/A
- GPCR N/A
- Industry
- VRNT EDP Services
- GPCR
- Sector
- VRNT Technology
- GPCR
- Exchange
- VRNT Nasdaq
- GPCR Nasdaq
- Market Cap
- VRNT 1.8B
- GPCR 1.8B
- IPO Year
- VRNT N/A
- GPCR 2023
- Fundamental
- Price
- VRNT $26.53
- GPCR $40.36
- Analyst Decision
- VRNT Buy
- GPCR Buy
- Analyst Count
- VRNT 8
- GPCR 6
- Target Price
- VRNT $35.00
- GPCR $81.33
- AVG Volume (30 Days)
- VRNT 865.6K
- GPCR 593.8K
- Earning Date
- VRNT 09-04-2024
- GPCR 08-08-2024
- Dividend Yield
- VRNT N/A
- GPCR N/A
- EPS Growth
- VRNT N/A
- GPCR N/A
- EPS
- VRNT 0.67
- GPCR N/A
- Revenue
- VRNT $915,103,000.00
- GPCR N/A
- Revenue This Year
- VRNT $4.89
- GPCR N/A
- Revenue Next Year
- VRNT $5.25
- GPCR N/A
- P/E Ratio
- VRNT $39.60
- GPCR N/A
- Revenue Growth
- VRNT 3.03
- GPCR N/A
- 52 Week Low
- VRNT $18.41
- GPCR $26.61
- 52 Week High
- VRNT $38.17
- GPCR $75.02
- Technical
- Relative Strength Index (RSI)
- VRNT 31.47
- GPCR 57.92
- Support Level
- VRNT $24.84
- GPCR $38.27
- Resistance Level
- VRNT $33.55
- GPCR $42.67
- Average True Range (ATR)
- VRNT 0.95
- GPCR 2.29
- MACD
- VRNT -0.37
- GPCR 0.31
- Stochastic Oscillator
- VRNT 19.52
- GPCR 76.72
About VRNT Verint Systems Inc.
Verint Systems Inc with its subsidiaries helps brands provide Boundless Customer Engagement. The company's solutions help iconic brands close the gap created when it lacks the resources required to deliver experiences that fulfill customer expectations. Geographically, it derives a majority of its revenue from the United States.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.